481658-94-0

Usage

Uses

Used in Veterinary Medicine:
Dirlotapid is used as an obesity treatment for companion animals, specifically dogs, by acting as a gMTP inhibitor. This helps in reducing the absorption and metabolism of dietary fats, thus aiding in weight management and overall health of the animals.

Veterinary Drugs and Treatments

Dirlotapide oral solution is indicated for the management of obesity in dogs.

Upstream product

• 71056-58-1 5-amino-1-methyl-1H-indole-2-carboxylic acid ethyl ester 
• 481659-93-2 ethyl 1-methyl-5-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamido]-1H-indole-2-carboxylate 
• 481659-95-4 C₂₄H₁₇F₃N₂O₃ 
• 171856-35-2 (S)-2-amino-N-benzyl-N-methyl-2-phenyl-acetamide 
• 84392-17-6 4'-(trifluoromethyl)-2-biphenylcarboxylic acid 

Relevant academic research and scientific papers

In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity

The synthesis of a novel gut selective MTP inhibitor, 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), and its in vitro and in vivo profile are described. Dirlotapide (3) demonstrate

Triamide-substituted heterobicyclic compounds

The invention relates to triamide MTP/ApoB inhibitors of the formula 1 wherein R1-R8 are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.